Retatrutide is a weight management research compound currently in stock directly from a verified Chinese manufacturer. Product specifications are confirmed for the selected manufacturer and batch before the order is finalized. Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
Retatrutide (LY3437943) is an investigational, once-weekly triple agonist targeting the GIP, GLP-1 and glucagon receptors. Lilly has reported positive Phase 3 topline results from the TRIUMPH program. Retatrutide is not currently approved by the FDA.
Published clinical research has evaluated retatrutide in metabolic-disease research, including obesity, type 2 diabetes and related cardiometabolic endpoints. It remains an investigational compound.
Product specifications are confirmed for the selected manufacturer and batch before the order is finalized. All supply is for laboratory research use only and is not for human consumption.
| Chemical Class | Investigational triple receptor agonist |
|---|---|
| Synonyms | LY3437943 |
| Mechanism | GLP-1R / GIPR / GcgR triple agonist |
| Clinical Status | Investigational; positive Phase 3 topline results reported from the TRIUMPH program; not FDA-approved |
| Research Areas | Obesity, metabolic syndrome, type 2 diabetes, MASH/NAFLD, cardiovascular risk markers, thermogenesis |
| Form | Lyophilized powder |
| Storage | −20°C, protect from light and moisture |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| Retatrutide | 5 mg | 10 vials | ≥98% | Out of Stock | $72.00 |
| Retatrutide | 5 mg | 10 vials | — | In Stock | $94.00 |
| Retatrutide | 10 mg | 10 vials | — | In Stock | $125.00 |
| Retatrutide | 10 mg | 10 vials | ≥98% | In Stock | $110.00 |
| Retatrutide | 15 mg | 10 vials | ≥98% | In Stock | $132.00 |
| Retatrutide | 15 mg | 10 vials | — | In Stock | $163.00 |
| Retatrutide | 20 mg | 10 vials | — | In Stock | $200.00 |
| Retatrutide | 20 mg | 10 vials | ≥98% | Out of Stock | $145.00 |
| Retatrutide | 30 mg | 10 vials | — | In Stock | $250.00 |
| Retatrutide | 30 mg | 10 vials | ≥98% | In Stock | $200.00 |
| Retatrutide | 40 mg | 10 vials | — | In Stock | $300.00 |
| Retatrutide | 40 mg | 10 vials | >=98% | In Stock | $263.00 |
Phase 2 clinical research data on retatrutide demonstrated dose-dependent bodyweight reductions exceeding those reported for tirzepatide and semaglutide at comparable time points. The addition of glucagon receptor agonism to dual GLP-1/GIP activity is investigated for additive fat oxidation and thermogenesis effects — mechanisms being studied in the context of severe obesity and metabolic disease.
As a GLP-1R agonist, retatrutide carries glucose-lowering activity through incretin-mediated insulin secretion and glucagon suppression. Phase 2 published data showed meaningful HbA1c reductions alongside substantial bodyweight effects in participants with type 2 diabetes, establishing it as a subject of interest in multi-factorial metabolic disease research.
Emerging research interest follows the cardiovascular outcome data from related GLP-1 class compounds and early signals from retatrutide's Phase 2 data regarding liver fat reduction in MASH/NAFLD models. Cardiovascular risk marker changes observed in Phase 2 are being monitored in the ongoing Phase 3 program as secondary endpoints.
Semaglutide is a GLP-1R mono-agonist. Tirzepatide adds GIP receptor activity as a dual agonist. Retatrutide also targets the glucagon receptor, making it an investigational triple agonist.
Retatrutide remains investigational. Lilly has reported positive Phase 3 topline results from the TRIUMPH program, and retatrutide is not currently approved by the FDA.
Product specifications are confirmed for the selected manufacturer and batch before the order is finalized.
Lyophilized retatrutide should be stored at −20°C, protected from light and moisture.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.